Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liraglutide for weight management in paediatric Prader–Willi syndrome
2014-004415-37Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Jul 2015
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Prader-Willi syndrome (PWS) and obesity comparing Liraglutide with Placebo / no treatment control (2 arms). Primary endpoints: Change in BMI standard deviation score at 16 weeks and Change in BMI standard deviation score at 52 weeks. Started Jul 2015; status: completed.
02
Drugs
03
Conditions
Prader-Willi syndrome (PWS)obesity
Beyond the preview
Go deeper on 2014-004415-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004415-37.